Navigation Links
Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial
Date:12/22/2009

rteries'.

The primary objective of this study is to determine if RVX-208 will produce an increase in plasma ApoA-l levels compared to placebo group after three months of dosing. The secondary objectives are to examine the safety and tolerability of RVX-208, to compare the dose and time response relationships for ApoA-l over time as well as to examine and key reverse cholesterol makers such as Alpha 1 HDL.

"The initiation of the ASSERT Trial is another important milestone that Resverlogix has achieved this year. Our clinical trials to date have produced very encouraging results for our lead drug, RVX-208, for the treatment of atherosclerosis. Currently, there is a void in therapies that can regress atherosclerosis. The current standard of care is statin therapies, which can only stop atherosclerosis from progressing but in almost all cases is unable to remove it. If RVX-208 is able to achieve this goal it would be an important step toward the reduction of disease risk and lower health system costs. We are delighted to have this trial dose its first patients two months ahead of schedule," said Donald J. McCaffrey, President and CEO of Resverlogix.

About RVX-208

RVX-208, a novel small molecule therapeutic that facilitates endogenous ApoA-I production, is positioned to be one of the most promising emerging drugs in the treatment of atherosclerosis. To the Company's knowledge RVX-208 is the only novel small molecule that is specifically designed to increase ApoA-I production and thereby raise HDL levels thus enhancing HDL functionality to augment reverse cholesterol transport (RCT). RCT is a pathway by which accumulated cholesterol is transported from the arterial wall to the liver for excretion, thus preventing atherosclerosis.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Resverlogix Updates Shareholders on Accelerated Clinical Trial Plan
2. Resverlogix Appoints A. Brad Cann as Chief Financial Officer
3. Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
4. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
5. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
6. Resverlogix Provides Quarterly Update
7. Resverlogix Board of Directors Update
8. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
9. Resverlogix Announces Closing of Debt Redemption
10. Resverlogix Eliminates Sixty Percent of Remaining Debt
11. Resverlogix Issues a Management Statement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... (PRWEB) May 21, 2013 Savoury Systems ... has appointed Dale Braddy to Southeastern USA Sales Broker. ... its sales muscle in the Southeast. , ... ingredient brokerage and supplier to food processors and industrial ... years in the food industry and has over 25 ...
(Date:5/21/2013)... According to a new market ... "Biochip Products and Services Market (Microarrays, Reagents, Drug Discovery, ... Share, Growth, Trends and Forecast, 2012 - 2018," the market was valued ... to grow at a CAGR of 10.1% from 2012 ... 4.7 billion in 2018. Browse the full ...
(Date:5/21/2013)... 2013 Emerson Resources Inc. , ... Charles Signorino, the Company’s Chief Executive Officer and Chairman ... 32 years of service. As part of Emerson Resources’ ... has been named as Dr. Signorino’s successor. , ... industry, having made a significant contribution to the field ...
(Date:5/21/2013)... 21, 2013  Personal Genome Diagnostics Inc. (PGDx), ... methodologies and expertise in genomic analysis of defined ... collaboration with Blueprint Medicines.  PGDx is an innovator ... alterations in tumors, and Blueprint Medicines is an ... a genetically defined patient population. "This ...
Breaking Biology Technology:The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5Emerson Resources Announces CEO Retirement and Appointment of Successor 2Emerson Resources Announces CEO Retirement and Appointment of Successor 3Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 3
... new facility, based in Los Angeles, California is anticipated ... ability to supply its new, generation of ... ANGELES, Oct. 6 Today, Grifols SA (Grifols), a,global ... a new,92,000 square foot, intravenous immune globulin (IVIG) production ...
... ANTWERP and AALST , Belgium, AHMEDABAD, India ... Research, genae associates,Cardiovascular Center Aalst and J.B. ... a Core Laboratories joint venture, called imaeon., ... performance of medical images,analysis for clinical research ...
... deCODE genetics,(Nasdaq: DCGN ) today announced that ... Nasdaq Stock Market stating that for 10 consecutive trading,days ... below $50 million,the minimum level required for continued listing ... Marketplace Rule 4450(b)(1)(A). The notice,further stated that deCODE also ...
Cached Biology Technology:Grifols Breaks Ground on New IVIG Facility 2Core Laboratories Joint Venture Agreement Between genae associates, VIBGYOR Scientific Research, Cardiovascular Center Aalst and J.B. Dahm 2deCODE Receives Nasdaq Deficiency Notice Relating to Market Value 2deCODE Receives Nasdaq Deficiency Notice Relating to Market Value 3
(Date:5/21/2013)... When infections occur in the body, stem cells ... multiplying and differentiating into mature immune cells that ... inflammation can deplete these cell populations, potentially leading ... as cancer. Now, a team of researchers led ... (Caltech) has found that, in mouse models, the ...
(Date:5/21/2013)... phosphatidylserine is a natural food supplement produced from ... and slow memory loss, it,s a popular treatment ... team headed by Prof. Gil Ast and Dr. ... Human Molecular Genetics have discovered that ... involved in degenerative brain disorders, including Parkinson,s disease ...
(Date:5/21/2013)... , Where? Copenhagen, Denmark: Bella Center Congress ... , Why? An annual meeting ... developments, manufacturing and installation, drawing on leading experiences from ... edition from a record of more than 900 abstracts ... plenary and oral presentations, more than 460 visual presentation, ...
Breaking Biology News(10 mins):Keeping stem cells strong 2Common food supplement fights degenerative brain disorders 221st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4
... (November 10, 2008) Conservation International (CI) today announced ... SKG, Inc. (NYSE: DWA) in support of its conservation ... in Los Angeles at an event launch for the ... Kung Fu Panda, the Company and its Chief Executive ...
... International Journal of Social Robotics , an important addition to ... to provide an overview of the current state of the ... set to evolve in the future and their impact on ... Robotics will cover a broad array of topics related ...
... that racing cars and bicyclists can reduce air resistance ... New York University and Cornell University have found the ... Their study, published in the most recent issue of ... in a series of flags, the leading flag faces ...
Cached Biology News:Conservation International gets support from Dreamworks Animation to protect giant pandas 2International Journal of Social Robotics debuts at Springer 2Lead-flapping objects experience less wind resistance than their trailing counterparts 2
... FACSVantageTM SE flow cytometry system is the ... For over 25 years, BD cell sorters ... found in leading university, pharmaceutical, and biotechnology ... meet the research demands of today, we ...
Reacti-Bind DNA Coating Solution...
... The versatile ST-195 allows real-time observations ... conditions. This instrument has 64 different strain ... CO2 incubator. The thin silicon strain chamber ... inverted microscopes and fluorescence microscopy. ST-195 can ...
... Control and regulate cell stretching or compression ... microscope stage. Computer controlled so you can ... the strain to produce 64 unique strain ... then the ST-150. Both models are compatible ...
Biology Products: